[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529275":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":71,"collaborators":73,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":10,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":10,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,16,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Surgical Procedure (Arthroplasty)",null,"PPSP subjects who have undergone hip (or knee) joint arthroplasty (i.e., open surgical procedure for joint replacement).\n\n* 6 month post-op scans\n* 12 month post-op scans\n* 18 month post-op scans",[13,14,15],"Drug: FDG radiotracer","Device: PET\u002FMRI","Device: PET\u002FCT imaging",{"label":17,"type":10,"description":18,"interventionNames":19},"Less Invasive Procedure (Arthroscopy)","PPSP subjects who have undergone hip (or knee) arthroscopy (i.e., less invasive joint surgical procedure involving scopes and lower profile surgical tools)\n\n\\- 6 month post-op scans",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Asymptomatic: Had Total Joint Replacement (Arthroplasty)","Asymptomatic subjects who have undergone total hip or total knee arthroplasty.\n\n\\- single scan during one study visit (up to 3.5 hours)",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Asymptomatic: Less Invasive Procedure (Arthroscopy)","Asymptomatic subjects who have undergone hip or knee arthroscopy.\n\n\\- single scan during one study visit (up to 3.5 hours)",[13,14,15],[29,37,42],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","FDG radiotracer","Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\\[18F\\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi\u002Fkg\u002Fpatient.",[21,25,17,9],[35,36],"fluorodeoxyglucose","18F-Fluorodeoxyglucose",{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"DEVICE","PET\u002FMRI","positron emission tomography and magnetic resonance imaging",[21,25,17,9],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"PET\u002FCT imaging","positron emission tomography and computed tomography imaging",[21,25,17,9],[47],{"name":48,"affiliation":5,"role":49},"Sandip Biswal, MD","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":10,"email":55},"Radiology Studies","CONTACT","608-282-8349","Radstudy@uwhealth.org",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":10},"UW School of Medicine and Public Health","RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-89.40123,43.07305,{"lat":69,"lon":68},{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[74,77],{"name":75,"class":76},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",{"name":78,"class":79},"Arthroscopy Association of North America (AANA)","UNKNOWN","100529275","fdg-petmr-imaging-of-peripheral-pain-generators-100529275",false,"NCT06171659","FDG PET\u002FMR Imaging of Peripheral Pain Generators","FDG PET\u002FMR Imaging of Peripheral Pain Generators in Persistent Post-Surgical Pain (PPSP)","Inclusion Criteria: Persistent Post-Surgical Pain Patients\n\n* 18-85 years old\n* Presents with persistent pain with pain score of ≥4 on Numerical Rating Scale \\[0:10\\] for at least 6 months following joint arthroplasty or arthroscopy.\n* Able and willing to provide informed consent\n* Willing and able to undergo PET\u002FMRI (arthroplasty and arthroscopy participants) and PET\u002FCT (arthroplasty participants only)\n\nInclusion Criteria: Asymptomatic controls\n\n* 18-85 years old\n* Asymptomatic (pain score of ≤2 on the NRS) for at least 6 months following joint arthroplasty or arthroscopy.\n* Able and willing to provide informed consent\n* Willing and able to undergo PET\u002FMRI\n\nExclusion Criteria:\n\n* Inability to understand and communicate with the investigators to complete the study-related questionnaires.\n* Any co-morbidity which results in severe systemic disease limiting function as defined by the American Society of Anesthesiology (ASA) physical status classification \\> 3, such as the presence of current or past (6 months) pulmonary, hepatic, renal disease, arthritis, hematopoietic, and neurological diseases not related to chronic pain.\n* Pregnant or breastfeeding. (Individuals with childbearing potential will be asked to verbally confirm they are not pregnant. If they cannot confirm, they will have a urine pregnancy test either at the imaging study visit or within 7 days prior to the imaging study visit.)\n* Subject with contraindication(s) to or inability to undergo PET\u002FMRI\n* Current diagnosis of malignancy of any kind. Participants in remission for at least two years and not undergoing any treatment may be considered per investigator discretion\n* Current enrollment in a scientific interventional or treatment study.\n* Subject unable or unwilling to provide informed consent",true,"ALL","18 Years","85 Years",{"count":92,"type":93},128,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to determine if a PET\u002FMRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.",[97,98],"Pain","Nociceptive Pain","2025-09-24",{"date":101,"type":102},"2025-09-25","ACTUAL",{"date":104,"type":102},"2024-11-19",{"date":106,"type":93},"2027-06",{"name":5,"class":6},1]